Antigen-specific tolerance induction is the ultimate goal for specific immunotherapy of autoimmune diseases. Here we will discuss recent experiments designed to induce tolerance following mucosal administration of antigens in a mouse model of experimental autoimmune encephalomyelitis (EAE). We were unable to induce oral tolerance either with whole myelin, myelin basic protein (MBP) or the immunodominant peptide antigen. Oral tolerance was possible, however, with an analogue of the immunodominant peptide modified to increase its affinity for the restricting major histocompatibility complex (MHC) antigen. By contrast, intranasal deposition of peptide antigen proved highly effective for both prevention and treatment of EAE. Prevention of disease was directly related to the antigenic property of the peptide which, in itself, was related to affinity for MHC. Notably, administration of a single peptide was shown to inhibit disease involving multiple epitopes. We investigated the resulting bystander regulation by studying the cellular basis of peripheral tolerance in a transgenic model. These studies indicate that bystander regulation may be the consequence of selective cytokine secretion.
|Pages (from-to)||120-31; discussion 131-6, 186-90|
|Journal||Novartis Foundation symposium|
|Publication status||Published - 1998|
- Administration, Intranasal
- Administration, Oral
- Encephalomyelitis, Autoimmune, Experimental
- H-2 Antigens
- Immune Tolerance
- Immunodominant Epitopes
- Major Histocompatibility Complex
- Models, Immunological
- Myelin Proteins
- Peptide Fragments
Anderton, S. M., Burkhart, C., Liu, G. Y., Metzler, B., & Wraith, D. C. (1998). Antigen-specific tolerance induction and the immunotherapy of experimental autoimmune disease. Novartis Foundation symposium, 215, 120-31; discussion 131-6, 186-90.